Gladstone Institutional Advisory’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$778K Sell
5,578
-4,208
-43% -$589K 0.03% 435
2025
Q4
$1.2M Buy
9,786
+166
+2% +$20.2K 0.05% 337
2025
Q3
$1.07M Buy
9,620
+1,301
+16% +$148K 0.04% 353
2025
Q2
$922K Buy
8,319
+43
+0.5% +$4.58K 0.04% 359
2025
Q1
$927K Buy
8,276
+4,661
+129% +$481K 0.04% 342
2024
Q4
$334K Sell
3,615
-289
-7% -$26K 0.02% 557
2024
Q3
$327K Sell
3,904
-9,014
-70% -$688K 0.02% 554
2024
Q2
$886K Buy
12,918
+182
+1% +$12.1K 0.05% 316
2024
Q1
$933K Sell
12,736
-819
-6% -$63K 0.05% 298
2023
Q4
$1.1M Sell
13,555
-252
-2% -$19.6K 0.06% 277
2023
Q3
$1.03M Buy
13,807
+511
+4% +$39.3K 0.07% 263
2023
Q2
$1.02M Sell
13,296
-97
-0.7% -$7.74K 0.06% 271
2023
Q1
$1.11M Sell
13,393
-2,158
-14% -$179K 0.07% 263
2022
Q4
$1.34M Buy
15,551
+452
+3% +$35.8K 0.09% 240
2022
Q3
$931K Buy
15,099
+1,180
+8% +$74.4K 0.07% 281
2022
Q2
$860K Buy
13,919
+1,084
+8% +$67.1K 0.07% 302
2022
Q1
$763K Buy
12,835
+1,050
+9% +$67.1K 0.05% 347
2021
Q4
$856K Buy
+11,785
New +$812K 0.07% 288
2020
Q4
Sell
-5,204
Closed -$329K 308
2020
Q3
$329K Buy
5,204
+1,497
+40% +$104K 0.08% 196
2020
Q2
$285K Sell
3,707
-4,631
-56% -$355K 0.07% 180
2020
Q1
$623K Buy
8,338
+4,837
+138% +$334K 0.16% 126
2019
Q4
$227K Sell
3,501
-497
-12% -$32.4K 0.06% 241
2019
Q3
$253K Buy
+3,998
New +$261K 0.06% 231

Other funds holding GILD

Gladstone Institutional Advisory's GILD Position: Q1 2026 in Review

Gladstone Institutional Advisory reduced its Gilead Sciences (GILD) stake by 43% in Q1 2026, selling an estimated $589K and leaving 5,578 shares worth $778K. The position accounts for 0.03% of the portfolio, ranked #435.

Gladstone Institutional Advisory first reported a position in GILD in Q3 2019 and has held it in 23 quarters since. The position peaked at $1.34M in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Gladstone Institutional Advisory held 5,578 shares of Gilead Sciences worth $778K as of Q1 2026.
  • Gladstone Institutional Advisory sold 4,208 Gilead Sciences shares in Q1 2026, an estimated $589K.
  • Gilead Sciences made up 0.03% of Gladstone Institutional Advisory's portfolio in Q1 2026, its #435 holding.
  • Gladstone Institutional Advisory first reported a position in Gilead Sciences in Q3 2019 and has held it in 23 quarters since.
  • Gladstone Institutional Advisory's Gilead Sciences position peaked at $1.34M in Q4 2022.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q1 2026, filed 14 May 2026.